Drug Trial Radar · NCT06527144
A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Last checked: Nov 20, 2026Latest source record: Apr 11, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
240
Actual
Start
Sep 14, 2024
Primary completion
Jan 16, 2025
Study completion Mar 6, 2025
Sponsor
- Lead sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 30, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy and safety of TQC3721 Suspension for Inhalation in patients with moderate to severe Chronic obstructive pulmonary disease (COPD)
Conditions
- Pulmonary Disease, Chronic Obstructive
Interventions
3mg TQC3721 Suspension for InhalationDrug
TQC3721 suspension for inhalation is target inhibitor.
6mg TQC3721 Suspension for InhalationDrug
TQC3721 suspension for inhalation is target inhibitor.
Placebo TQC3721 suspension for inhalationDrug
Placebo without active drug substance.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change of the maximum value of Forced Expiratory Volume in the first second (FEV1)Time frame: From baseline to four weeks after treatment
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Fu Yang People'S Hospital
Fuyang, Anhui, China
ChongQing University Fuling Hospital
Chongqing, Chongqing Municipality, China
The Second Affiliated Hospital of Xiamen Medical College
Xiamen, Fujian, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, Guangdong, China
The People's Hospital of Guangxi Zhuang Autonomous Region
Nanning, Guangxi, China
Zunyi Medical University Affiliated Hospital
Zunyi, Guizhou, China
Cangzhou Hospital of Integrated Tcm-Wm·Hebei
Cangzhou, Hebei, China
The Third Hospital of Hebei Medical University
Shijiazhuang, Hebei, China
Puyang Oilfield General Hospital
Puyang, Henan, China
Shangqiu First People's Hospita
Shangqiu, Henan, China
Chifeng Municipal Hospital
Chifeng, Inner Mongolia, China
Wuxi Fifth People's Hospital
Wuxi, Jiangsu, China
Yixing People'S Hospital
Wuxi, Jiangsu, China
Northern Jiangsu People's Hospital
Yangzhou, Jiangsu, China
Jiangxi Provincial People's Hospital
Nanchang, Jiangxi, China
The First Hospital of Jilin University
Changchun, Jilin, China
Siping Central People's Hospital
Siping, Jilin, China
Genertec Liaoyou Gem Flower Hospital
Panjin, Liaoning, China
Heze Municipal Hospital
Heze, Shandong, China
Shanghai JiaoTong University of medicine Ruijin Hospital
Shanghai, Shanghai Municipality, China
Shanxi Bethune Hospital
Taiyuan, Shanxi, China
West China Hospital of Sichuan University
Chengdu, Sichuan, China
Suining Central Hospital
Suining, Sichuan, China
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
TianJin 4th Center Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Shihezi University
Shihezi, Xinjiang, China
Wenzhou University Affiliated Second Hospital
Wenzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.